Ding Ya-Hui, Ma Yuan, Qian Lin-Yan, Xu Qiang, Wang Li-Hong, Huang Dong-Sheng, Zou Hai
Department of Cardiology, Zhejiang Provincial People's Hospital, Hangzhou 310014, China.
People's Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, China.
Oncotarget. 2017 Jul 24;8(36):60673-60683. doi: 10.18632/oncotarget.19522. eCollection 2017 Sep 1.
Non-alcoholic fatty liver disease (NAFLD) and atrial fibrillation (AF) are common chronic non-infectious diseases with rising incidences. NAFLD is an independent risk factor for the onset of AF, after adjusting potentially related factors. The pathogenesis of these diseases share several mechanisms including reduced adiponectin level, insulin resistance, and renin angiotensin aldosterone system (RAAS) activation, in addition to activation of common disease pathways that promote inflammation, oxidative stress, and fibrosis. Furthermore, statins and RAAS blockers exert therapeutic effects concurrently on NAFLD and AF. The common pathogenesis of NAFLD and AF may serve as a potential therapeutic target in the future.
非酒精性脂肪性肝病（NAFLD）和心房颤动（AF）是发病率不断上升的常见慢性非传染性疾病。在调整潜在相关因素后，NAFLD是AF发病的独立危险因素。这些疾病的发病机制有几个共同的机制，包括脂联素水平降低、胰岛素抵抗和肾素血管紧张素醛固酮系统（RAAS）激活，此外还有促进炎症、氧化应激和纤维化的常见疾病途径的激活。此外，他汀类药物和RAAS阻滞剂对NAFLD和AF同时发挥治疗作用。NAFLD和AF的共同发病机制可能在未来成为一个潜在的治疗靶点。
